about

Title1850.The start

Sir George Grey served as a Governor of the Cape of Good Hope...
Read more

Lennon establishes himself

By 1858 the local press were featuring advertisements detailing the Lennon products, which had just arrived by ship and were available in pharmacies.
Read more

1884. Advertisement in the first South African Medical Journal

The first issue of the publication...
Read more

1898. Lennon Limited is born

By 1898, due to the tremendous expansion...
Read more

1899. First annual report

The first annual report noted a satisfactory performance despite...
Read more

1911. Lennon is widely established

By 1911, Lennon Ltd...
Read more

1930. Lennon – largest in the southern hemisphere

In 1930 Lennon Ltd was the largest pharmaceutical company...
Read more

1957. 30 June 1957 financials

During the 1950s and 1960s Lennon Ltd...
Read more

1967. The Lennon factory in Port Elizabeth

View from the North End Lake, showing the Welfare Block in the foreground...
Read more

1975. Lennon – a generic front runner

The Medicines and Related Substances Act of 1965 prompted most...
Read more

1996. SA Druggists

In 1968 the South African Druggists group, including Lennon Ltd, was listed on the Johannesburg Stock Exchange...
Read more

1997. Humble beginnings

Stephen Saad and Gus Attridge were two of the four founding members of Aspen...
Read more

1998. JSE listing

Aspen was listed on the JSE through reverse listing into Medhold Ltd.
Read more

1999. SA Druggists acquired

Aspen acquired South African Druggists, the oldest pharmaceutical business in South Africa...
Read more

2001. Aspen Australia opens

Aspen Australia commenced as a start-up operations in Sydney and...
Read more

2002. Aspen’s new corporate identity

Aspen’s new corporate identity was launched symbolising energy, innovation and nurturing.
Read more

Title2002. CEPPWAWU deal

Aspen concluded a broad-based black economic empowerment deal with...
Read more

2003. First generic ARV launched

Aspen Stavudine was launched – Africa’s first generic antiretroviral (ARV).
Read more

2004. PE facility construction

Aspen’s state-of-the-art, multi-million Rand oral solid dose...
Read more

2004. Fine Chemicals

Aspen acquired Fine Chemicals in Cape Town, the only South African manufacturer of active pharmaceutical ingredients.
Read more

2004. Infacare acquisition

Aspen acquired Infacare, the infant nutritional brand, from Dutch-based Royal Numico.
Read more

2005. US FDA approval

Aspen’s Unit 1 facility in Port Elizabeth became the world’s first manufacturing facility to receive tentative US FDA approval for the production of certain generic ARVs.
Read more

2005. Imithi transaction

Aspen extended its broad-based black economic empowerment ownership through an empowerment transaction with Imithi Investments (Pty) Ltd.
Read more

2006. Aspen largest supplier of ARVs in Africa

Aspen was recognised as the largest supplier of ARVs in Africa...
Read more

2006. Manufacturing and capacity enhancements

Construction commenced on the Sterile Facility at the Port Elizabeth site.
Read more

2008. Aspen enters Latin America

Aspen entered the Latin American market through an investment in businesses established in Brazil, Mexico and Venezuela and...
Read more

2008. GSK product acquisition

Aspen acquired the intellectual property rights from GSK for four key global brands: Eltroxin, Imuran, Lanoxin and Zyloric...
Read more

2009. Further GSK transactions

Aspen concluded a series of strategic transactions with GSK comprising the acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa...
Read more

2011. Aspen expands its Australian presence

Aspen started its business in 2001 with two people. In 2011 Aspen acquired the largest...
Read more

2011. Aspen embraces Mandela Day

Aspen joined the call of the Former South African President Nelson Mandela in support of an annual event to benefit disadvantaged communities.
Read more

2012. Aspen joins Social Compact

Aspen signalled its support of the Social Compact, as a founder member of the Public Healthcare Enhancement Fund in South Africa...
Read more

2013. Expansion of Aspen’s infant nutritional products

2013 heralded Aspen’s acquisition of rights to infant nutritional brands and related businesses from Nestlé in Australia, a number of Latin American territories...
Read more

2013. Branded products and API site acquired from MSD

Aspen acquired an API manufacturing business, primarily at Oss in the Netherlands (effective 1 October 2013), and a portfolio of 11 branded finished dose form molecules...
Read more

2014. Acquisition of anticoagulants from GSK

Aspen concluded two related transactions with GSK, valued at approximately R12 billion, to acquire the Arixtra and Fraxiparine/Fraxodi thrombolytic brands worldwide...
Read more

2014. Aspen goes global

Aspen expanded its global footprint, commencing activity in an additional 21 countries and taking the number of Aspen offices and sites around the world to more than 50.
Read more

2015. New global headquarters complete

New global headquarters complete.
Read more

2016 - Exclusive Rights to anaesthetics

Acquired the exclisive rights to commercialise AstraZeneca's global anaesthetics portfolio in 100 countries worldwide, including China but excluding the USA
Read more